Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study
- PMID: 30343026
- DOI: 10.1016/S2352-3018(18)30215-7
Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study
Abstract
Background: HIV pre-exposure prophylaxis (PrEP) is highly effective in men who have sex with men (MSM) at the individual level, but data on population-level impact are lacking. We examined whether rapid, targeted, and high-coverage roll-out of PrEP in an MSM epidemic would reduce HIV incidence in the cohort prescribed PrEP and state-wide in Australia's most populous state, New South Wales.
Methods: The Expanded PrEP Implementation in Communities-New South Wales (EPIC-NSW) study is an implementation cohort study of daily co-formulated tenofovir disoproxil fumarate and emtricitabine as HIV PrEP. We recruited high-risk gay men in a New South Wales-wide network of 21 clinics. We report protocol-specified co-primary outcomes at 12 months after recruitment of the first 3700 participants: within-cohort HIV incidence; and change in population HIV diagnoses in New South Wales between the 12-month periods before and after PrEP roll-out. The study is registered with ClinicalTrials.gov, number NCT02870790.
Findings: We recruited 3700 participants in the 8 months between March 1, 2016, and Oct 31, 2016. 3676 (99%) were men, 3534 (96%) identified as gay, and 149 (4%) as bisexual. Median age was 36 years (IQR 30-45 years). Overall, 3069 (83%) participants attended a visit at 12 months or later. Over 4100 person-years, two men became infected with HIV (incidence 0·048 per 100 person-years, 95% CI 0·012-0·195). Both had been non-adherent to PrEP. HIV diagnoses in MSM in New South Wales declined from 295 in the 12 months before PrEP roll-out to 221 in the 12 months after (relative risk reduction [RRR] 25·1%, 95% CI 10·5-37·4). There was a decline both in recent HIV infections (from 149 to 102, RRR 31·5%, 95% CI 11·3 to 47·3) and in other HIV diagnoses (from 146 to 119, RRR 18·5%, 95% CI -4·5 to 36·6).
Interpretation: PrEP implementation was associated with a rapid decline in HIV diagnoses in the state of New South Wales, which was greatest for recent infections. As part of a combination prevention approach, rapid, targeted, high-coverage PrEP implementation is effective to reduce new HIV infections at the population level.
Funding: New South Wales Ministry of Health, Gilead Sciences.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Comment in
-
What happens when PrEP is scaled up? Results from EPIC-NSW.Lancet HIV. 2018 Nov;5(11):e607-e608. doi: 10.1016/S2352-3018(18)30253-4. Epub 2018 Oct 17. Lancet HIV. 2018. PMID: 30343027 No abstract available.
Similar articles
-
Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.BMC Public Health. 2018 Feb 2;18(1):210. doi: 10.1186/s12889-017-5018-9. BMC Public Health. 2018. PMID: 29394918 Free PMC article. Clinical Trial.
-
Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.Lancet HIV. 2021 Aug;8(8):e486-e494. doi: 10.1016/S2352-3018(21)00074-6. Epub 2021 Jul 1. Lancet HIV. 2021. PMID: 34217426
-
On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.Lancet HIV. 2020 Feb;7(2):e113-e120. doi: 10.1016/S2352-3018(19)30341-8. Epub 2019 Nov 26. Lancet HIV. 2020. PMID: 31784343 Clinical Trial.
-
Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.Pharmacotherapy. 2019 Apr;39(4):486-500. doi: 10.1002/phar.2240. Epub 2019 Apr 1. Pharmacotherapy. 2019. PMID: 30815960 Free PMC article. Review.
-
Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool.Sex Transm Infect. 2017 Aug;93(5):363-367. doi: 10.1136/sextrans-2016-052699. Epub 2016 Nov 21. Sex Transm Infect. 2017. PMID: 27872326 Review.
Cited by
-
Advances in HIV management and challenges in Japan: Current situation of pre-exposure prophylaxis in Tokyo.Glob Health Med. 2024 Oct 31;6(5):304-309. doi: 10.35772/ghm.2024.01043. Glob Health Med. 2024. PMID: 39483446 Free PMC article. Review.
-
Preparing for the Implementation of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis Within the Brazilian Public Health System (ImPrEP CAB Brasil): Qualitative Study.JMIR Public Health Surveill. 2024 Oct 24;10:e60961. doi: 10.2196/60961. JMIR Public Health Surveill. 2024. PMID: 39446416 Free PMC article.
-
A Systematic Review and Meta-analysis of the Impact of the COVID-19 Pandemic on Access to HIV Pre-exposure Prophylaxis: Lessons for Future Public Health Crises.J Acquir Immune Defic Syndr. 2024 Nov 1;97(3):208-215. doi: 10.1097/QAI.0000000000003488. Epub 2024 Oct 7. J Acquir Immune Defic Syndr. 2024. PMID: 39431504 Free PMC article.
-
New horizons in sexual health: exploring PrEP and HIV incidence in adolescents.Rev Saude Publica. 2024 Oct 11;58(suppl 1):2s. doi: 10.11606/s1518-8787.2024058supl1ap. Rev Saude Publica. 2024. PMID: 39417512 Free PMC article. No abstract available.
-
Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022.Euro Surveill. 2024 Sep;29(38):2400083. doi: 10.2807/1560-7917.ES.2024.29.38.2400083. Euro Surveill. 2024. PMID: 39301743 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
